II. Details: Therapeutic Agents for Chronic Heart Failure; 6. Vericiguat

[1]  B. Pieske,et al.  Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction , 2021, Clinical Pharmacokinetics.

[2]  D. Kass,et al.  Cellular and molecular pathobiology of heart failure with preserved ejection fraction , 2021, Nature Reviews Cardiology.

[3]  P. Ponikowski,et al.  N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. , 2020, JACC. Heart failure.

[4]  A. Friebe,et al.  cGMP: a unique 2nd messenger molecule – recent developments in cGMP research and development , 2019, Naunyn-Schmiedeberg's Archives of Pharmacology.

[5]  Dong Ik Lee,et al.  Marked disparity of microRNA modulation by cGMP-selective PDE5 versus PDE9 inhibitors in heart disease. , 2018, JCI insight.

[6]  Sanjiv J. Shah,et al.  Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. , 2015, JAMA.

[7]  D. Kass,et al.  Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. , 2009, Pharmacology & therapeutics.

[8]  A. Ferreira,et al.  The cyclic guanosine monophosphate/B‐type natriuretic peptide ratio and mortality in advanced heart failure , 2009, European journal of heart failure.

[9]  T. Izumi,et al.  Cyclic GMP production by ANP, BNP, and NO during worsening and improvement of chronic heart failure. , 2003, Japanese heart journal.